why choose us

First received: June 05, 2023

Clinical Trial: POC Study to Evaluate BSI-045B in Moderate-to-severe Atopic Dermatitis

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Atopic Dermatitis

Study Type: INTERVENTIONAL


Official Title: A Phase 2a, Multicenter, Proof-of-Concept Clinical Trial to Evaluate Efficacy and Safety of BSI-045B mAb Injection in Patients With Moderate to Severe Atopic Dermatitis

Brief Summary: The study is a multicenter clinical trial and is designed as a proof-of-concept study to evaluate the efficacy, safety, tolerability, PK, immunogenicity, and PD of BSI-045B following SC injections.The study will enroll patients with moderate to severe AD to receive the 300 mg treatment.BSI-045B wil be firstly given weekly during Week 1 to Week 4, and then every 2 weeks (Q2W) to Week 24.

Read more